402 related articles for article (PubMed ID: 32360516)
1. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
2. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
3. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
4. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
5. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
6. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
Stahel PF; Barnum SR
Front Immunol; 2020; 11():1661. PubMed ID: 32733489
[No Abstract] [Full Text] [Related]
7. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
8. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
9. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
10. Surviving COVID-19: A disease tolerance perspective.
Ayres JS
Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
[No Abstract] [Full Text] [Related]
11. COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E; Tsiodras S
EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
[TBL] [Abstract][Full Text] [Related]
12. Case Report: The First Case of COVID-19 in Bhutan.
LeVine S; Dhakal GP; Penjor T; Chuki P; Namgyal K; Tshokey ; Watts M
Am J Trop Med Hyg; 2020 Jun; 102(6):1205-1207. PubMed ID: 32314685
[TBL] [Abstract][Full Text] [Related]
13. Imatinib for COVID-19: A case report.
Morales-Ortega A; Bernal-Bello D; Llarena-Barroso C; Frutos-Pérez B; Duarte-Millán MÁ; García de Viedma-García V; Farfán-Sedano AI; Canalejo-Castrillero E; Ruiz-Giardín JM; Ruiz-Ruiz J; San Martín-López JV
Clin Immunol; 2020 Sep; 218():108518. PubMed ID: 32599278
[No Abstract] [Full Text] [Related]
14. Early Insights into Immune Responses during COVID-19.
St John AL; Rathore APS
J Immunol; 2020 Aug; 205(3):555-564. PubMed ID: 32513850
[TBL] [Abstract][Full Text] [Related]
15. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
Mellors J; Tipton T; Longet S; Carroll M
Front Immunol; 2020; 11():1450. PubMed ID: 32733480
[TBL] [Abstract][Full Text] [Related]
16. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
17. Covid-19: Time for a paradigm change.
Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
[No Abstract] [Full Text] [Related]
18. Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Laforge M; Elbim C; Frère C; Hémadi M; Massaad C; Nuss P; Benoliel JJ; Becker C
Nat Rev Immunol; 2020 Sep; 20(9):515-516. PubMed ID: 32728221
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression in hematological cancer patients with Covid-19 -Uncomplicated infections but delayed viral clearance?
Boyd K; Parcell B; Tauro S
Leuk Res; 2020 Sep; 96():106407. PubMed ID: 32652329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
